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Targets of Antimicrobials 
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 
1. Cell wall inhibitors 
Block synthesis and repair 
 Penicillins 
 Cephalosporins 
 Carbapenems 
 Vancomycin 
 Bacitracin 
 Fosfomycin 
 Isoniazid 
2. Cell membrane 
Causelossofselective permeability 
 Polymyxins 
 Daptomycin 
3. DNA/RNA 
Inhibit replication and transcription 
 Inhibit gyrase(unwinding enzyme) 
     Quinolones 
 Inhibit RNA polymerase 
     Rifampin 
Ribosome 
mRNA DNA 
4. Protein synthes is inhibitors acting 
    on ribosomes 
Site of action 
50S subunit 
Erythromycin 
Clindamycin 
Synercid 
Pleuromutilins 
Site of action 
30S subunit 
Aminoglycosides 
    Gentamicin 
    Streptomycin 
Tetracyclines 
Glycylcyclines 
Both 30S 
and 50S 
Blocks initiation of protein 
synthesis 
    Linezolid 
5. Folic acid synthesis 
Block pathways and inhibit 
metabolism 
     Sulfonamides (sulfa drugs) 
     Trimethoprim 
Substrate 
Enzyme 
Product 
 Major Antimicrobial Drug Groups 
• About 260 different antimicrobial drugs 
• Classified in 20 drug families 
• Largest number of antimicrobial drugs are for 
bacterial infections 
– Antibiotic Source:  
• fungi and bacteria 
• semi-synthetic compounds 
Spectrum of Activity 
Aminoglycoside Drugs 
 
– Products of various species of soil actinomycetes in 
the genera Streptomyces and Micromonospora 
– Relatively broad spectrum because they inhibit 
protein synthesis 
– Subgroups and uses 
• Aerobic gram-negative rods and certain gram-positive 
bacteria 
• Streptomycin:  Bubonic plague and tularemia and good anti-
tuberculosis agent 
• Gentamicin:  Less toxic and used for gram-negative rods 
 
Resistance Mechanisms 
• Antibiotics are present in nature 
• Microbes are capable of adapting quickly to 
selective pressures 
• Drug resistance has arisen for all antibiotics 
• ESKAPE pathogens 
• Two main strategies employed by microbes 
– Prevent access of the drug to the target site 
– Alter the nature of the target site 
Antibiotic Resistance 
Not drug-resistant 
Drug-resistant mutant 
(a) Population of microbial cells (b) Sensitive cells (     ) eliminated by drug; 
 resistant mutants survive 
Remaining 
population 
grows 
overtime 
(c) All cells are now resistant 
Exposure 
to drug 
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Disk Diffusion Assays 
• Kirby-Bauer 
• Standardized 
conditions 
• Zones of inhibition 
• Larger zone 
indicates more 
susceptible 
• Smaller zone 
indicates more 
resistant 
S 
R 
R 
I 
I 
S 
1 2 3 4 0 5 
Kirby-Bauer Disc Diffusion Test* 
Oxytetracycline 30g 
(R<17 mm;S 22mm) 
Enrofloxacin 5 g 
(R < 17 mm;S 22 mm) Gentamicin 10 g 
(R < 17 mm; S 21 mm) 
OT 
30 
GN 
10 
CTX 
30 
AMP 
10 
C 
30 
Cefotaxime 30 g 
(R < 14 mm; S 23 mm) 
Ampicillin10g 
(R<14mm;S22mm) 
Chloramphenicol 30 g 
(R < 21 mm; S 21 mm) 
= Zone of Inhibition = Antibiotic carrier (disc) 
   imprinted with abbreviation 
   and concentration 
= Region of 
   bacterial growth 
Disc Diffusion Test (schematic). 
Example and evaluation of asensitivity test, agar diffusion method. 
R = resistant, I = intermediate, S = sensitive 
(a) *R and S values differ from table 12.7 due to differing concentrations of the antimicrobials. (b) 
ENR 
mm 
ENR 
5 
b: © Kathy Park Talaro  
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E-Test Strips 
• Drug gradient used 
• Can determine MIC 
• Read where the 
zone touches the 
strip 
 
DRUG DISCOVERY AND  
NATURAL PRODUCTS 
Starting point 
Research and development   
of drug or vaccines products is  
- demanding 
- risky 
How are they valued? 
$ 
Market value 
Societal value 
Vaccines 
Drugs 
The path toward a drug 
• In spite of pessimism; there are many antibacterial 
agents in clinical trials 
– Novel agents on the rise: last 85 years 
– Gram positive, gram negative and multi-drug resistant 
• 39 antibacterial compounds 
– 25 in Phase 2 or Phase 3 Trials 
• “Guarded optimism” 
– Renewed commitment from companies 
– Cubist (acquired Optimer and Trius Therapeutics), Roche 

Natural Products 
• Natural products originate from bacteria, fungus, plants or 
other natural sources (marine organisms) 
• Scaffold for many effective antibiotics (semi-synthetic)  
• Screening natural products is complicated 
– Complex mixture of secondary metabolites 
– Rediscovery of known active compounds 
• Dereplication to rule out knowns 
• Competition with HTS of synthesized compounds 
– Competition with HTS of synthesized compounds 
– Purified natural compounds exert challenge  
  
• Success (using in-vitro bioassay) depends on  
– Proper design, validation and implementation of screening assays 
• Natural products (NP) are a rich source of 
compounds for drug discovery (34%: 1981-2010) 
• Their use has decreased in the last 2 decades;  
barriers: NP screening in HTS against Targets 
• Review: technical advances to reduce barriers 
– Genomic and metabolomic approaches 
– Augment traditional methods of screening 
– Increased functional assays and phenotypic screen 
 
 
NCE: New Chemical entities 
  -NCEs are  small molecules 
NBE: New Biological entities 
  -biological products : 
  -proteins, antibodies, viruses    
               and vaccines. 
ADC: antibody drug conjugates 
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BACKGROUND 
• Bacteria in the order Actinomycetales account for 45% of the 
bioactive microbial metabolites discovered  
• These organisms have played a central role in the 
development of the modern pharmaceutical industry. 
• The search for novel antibiotics for use in medicine – 
important aspect of soil microbial diversity. 
 
                Objective of study: 
1) Collect soil samples from extreme environments of Kazakhstan 
2) Isolate & characterize extremophiles as potential producers of novel antibiotics 
  
Kazakhstan Extremophiles 
                   The purpose of this project is the study of biodiversity of extremophiles  and screening of 
 microorganism strains with the industrially valuable properties  from the soils of Kazakhstan. 
Collections and Selection of 
samples for analyses 
1.  The collection of soil and mud samples from 
extreme geographical zones of  Kazakhstan 
(solonchak, solonets, and solod soils, mineral 
water sources, anthropogenic area). 
2. Research of microorganism diversity in the 
extreme habitats (natural and anthropogenic). 
 
3. Isolation of pure strains of extremophiles from 
soils and muds. 
4. Study of antimicrobial activity of the 
extremophiles against gram-positive and gram-
negative test-organisms, including clinical 
resistant strains. 
 
5. Selection of strains with the potential for 
industrial application  and their id with PCR 
6. Creating a collection of extremophiles as 
producers of new industrially valuable biologically 
active substances. 
 
Some snap-shots of sites    
(North and South) in Kazakhstan 
Site 46-58 
Site 19 Site 33 
Site 48 
Site R 
Site Z3 
Methods and findings 
• Soil samples were plated following the dilution plating method on 
modified Bennett’s agar with  the following contents:  glucose – 
0.2%, peptone – 0.2%, yeast extract -0.1%,  agar -2%, рН 7.2.   
• Actinomycetes from the natural substrate samples were isolated on 
the three variants of modified Bennett’s agar:  
 #1 – modified Bennett’s agar, рН 7.2; 
 #2 - modified Bennett’s agar +5% NaCl, рН 7.2; 
 #3 - modified Bennett’s agar +0.5% Na2CO3, рН 9.0. 
• Bacterial strains:  hospital strain MRSA # 3316 and Escherichia coli 
(pMG223) were used in this study. 
• Actinomycetes isolates screened through 2 stages; disc diffusion 
method according to Barry, A.L. and C. Thornsberry*  
* Barry, A.L. and C. Thornsberry, 1985. Susceptibility Tests: Diffusion test procedure. In: Manual of Clinical Microbiology, 4th 
Edn., Ballows, E.A., W.J. Hawsler Jr and H.I. Shadomy (Eds.). American Society of Microbiology, Washington D C., pp: 978-987. 
Primary Screening: disc diffusion 
1) Actinomycetes from the natural substrate samples were isolated 
on the three variants of modified Bennett’s agar:  
    #1 – modified Bennett’s agar, рН 7.2; 
    #2 - modified Bennett’s agar +5% NaCl, рН 7.2; 
    #3 - modified Bennett’s agar +0.5% Na2CO3, рН 9.0. 
2) Pure culture was obtained and a lawn of bacteria was prepared 
3) Using cork-borer, the pure culture was transferred to a lawn of 
test organism (E.coli and S. aureus) 
Media #1 
Media #2…etc 
Crude screening: use cork-
borer to transfer 
Actinomycetes strains to 
lawn of test organisms  
1) Pure culture of test organism grown as a lawn 
2) MRSA # 3316 and Escherichia coli (pMG223)  
3) Zone of inhibition noted  
4) Extremophile culture condition that produces 
antagonistic activities determined  
Extraction - crude  
(not pure compound)… 
Crude Extraction  
Secondary Screening: disc diffusion 
1) Crude extracts (powder) was reconstituted to 
various concentrations 
2) These are applied in an aseptic manner to a 
set of sterile discs 
3) Dried discs are then placed on the lawn of 
test organisms 
1) Pure culture of test organism grown as a lawn 
2) MRSA (KZ) and Escherichia coli  (KZ), and MRSA 
(USA) and Acinetobacter baumannii (USA) 
3) Sterile discs containing known concentrations 
of extracts overlaid on the lawn  
4) Zone of inhibition noted  
5) Extracts (and concentrations) that produce 
antagonistic activities determined  
Chemical characterization, etc 
Sterile discs 
Crude Extracts 
Reconstituted 
Microbiological characterizations  
A. Extracts from Strain 91/1 against G+ pathogen
Top – growth on  medium 1, рН 7; then clockwise 
(medium 1, рН 9), (medium 1 + 0,25% Na2CO3),
(medium 1 + 0,375% Na2 CO3), 
(medium 1 + 0,5% Na2CO3), 
(medium 1 + 0,75% Na2CO3), (medium 1 + 1% Na2CO3).
Test-microorganism – S.aureus 209P, nutrient agar.
Fig 1. Antagonistic properties of extremophile actinomycetes in high 
salt media, varying pH conditions against Gram positive organisms
B. Extracts Strain 46/15 against G+ pathogens
Top – growth on salt-free medium 
(medium 1, рН 7), then clockwise 
(medium 1, рН 9), (medium 1 + 5% NaCl), 
(medium 1 + 7.5% NaCl), (medium 1 + 10% 
NaCl). Test-microorganism – S.aureus 209P, 
nutrient agar.
A B
  
Subgroups of actinomycetes 
 
 
Group IA            Subgroup IBa           Subgroup IBc            Subgroup ICa 
 
 
 
 
Subgroup IBb               Subgroup ICc         Subgroup  ICb 
 
  
Subgroup Antagonism in 
neutral habitat 
Antagonism in saline 
habitat 
Antagonism in alkaline 
habitat 
IA + + + 
IBa + + - 
IBb + - + 
IBc - + + 
ICa + - - 
ICb - + - 
ICc - - + 
IIAa + + no growth 
IIAb + no growth + 
IIAc no growth + + 
IIBa + - no growth 
IIBb - no growth + 
IIBc no growth + - 
Classification of actinomycetes based on  
ability to show antagonism in different habitats 
  
Subgroup Antagonism in 
neutral habitat 
Antagonism in saline 
habitat 
Antagonism in alkaline 
habitat 
IA + + + 
IBa + + - 
IBb + - + 
IBc - + + 
ICa + - - 
ICb - + - 
ICc - - + 
IIAa + + no growth 
IIAb + no growth + 
IIAc no growth + + 
IIBa + - no growth 
IIBb - no growth + 
IIBc no growth + - 
Classification of actinomycetes based on  
ability to show antagonism in different habitats 
  
Subgroup Antagonism in 
neutral habitat 
Antagonism in saline 
habitat 
Antagonism in alkaline 
habitat 
IA + + + 
IBa + + - 
IBb + - + 
IBc - + + 
ICa + - - 
ICb - + - 
ICc - - + 
IIAa + + no growth 
IIAb + no growth + 
IIAc no growth + + 
IIBa + - no growth 
IIBb - no growth + 
IIBc no growth + - 
Classification of actinomycetes based on  
ability to show antagonism in different habitats 
Streptomyces morphogenesis 
Developmental life cycle of  
Streptomyces coelicolor 
• Streptomyces largest genus of 
Actinobacteria, Order Actinomycetales and 
the type genus of family Streptomycetaceae 
• Gram positive bacilli, about 550 species 
• Found in soil and decaying vegetation 
• Spores, hyphae, mycelium 
• Regulatory genes: afsB, bldA, whiG 
• Diverse secondary metabolites 
• important role in life cycle in nature 
• Produce over 2/3 of the clinically useful 
antibiotics of natural origin 
• Chloramphenicol (from S. venezuelae) 
• Daptomycin (from S. roseosporus) 
• Neomycin (from S. fradiae) 
• Puromycin (from S. alboniger) 
• Streptomycin (from S. griseus) 
• Tetracycline (from S. rimosus and S. aureofaciens) 
• Antifungal of medicinal importance 
• nystatin (from S. noursei),  
• amphotericin B (from S. nodosus) 
 
Slide culture of a  
Streptomyces species 

Results 
• Actinomycetes strains analyzed based on their ability to show antagonism in the 
conditions of saline or alkaline environment;  
• 415 strains with antagonistic properties were selected:  
– antagonism against clinical MRSA strains (100%):  
– 21.6% had activities against E. coli 
– 28.4% against A. niger.  
 
• Changes in growth, morphogenesis, and antagonism of 415 strains of extremophile 
actinomycetes were determined in the habitats: neutral, saline, and alkaline.  
– The actinomycetes were classified into groups, subgroups, and variants.  
–  The "cosmopolitan"  (55.4%) dominated: grow and show antagonism in all studied habitats. 
 
• Two variants of actinomycetes whose antagonism is inversely related to their 
morphogenesis were determined.  
– The variant Q “quitters” (39.8%) antagonism correlated to good growth and formation of aerial mycelium 
– The variant F “fighters” (60.2%)  - antagonism correlated to the inhibition of growth and aerial mycelium. 
 
Pilot study  
(IMV - USF Collaboration) 
Project Focus and Goals 
Long term Focus of Collaboration 
Characterization of extremophiles obtained through 
screening of the producers of valuable antibiotics from 
unusual (extreme) ecosystems of Kazakhstan 
 
• The goal of the pilot project is to characterize a small 
sample of the extracts from Actinomycetes strains.  
– Compare susceptibility of extracts for antibiotics activity:  
Kazakhstan vs U.S. HAI pathogens (MRSA and Acinetobacter) 
– Chemical characterization and identification of putative active 
components (CDDI proteomics) 
Timeline of collaboration & project 
Sample preparation & Analyses 
Grant from International 
Scientific and Technology 
Center, Russia (2006) 
 Institute of Microbiology 
and Virology (IMV), 
Republic of Kazakhstan 
(2006-2012) 
(ECIA) Samples shipped to 
USF, USA (2011-2012) 
Travel Grant to IMV (2011) 
2012-2013: MRSA and Acinetobacter 
from Florida Hospital, USA 
Disc Diffusion /proteomics analyses 
Background  
• Methicillin-resistant Staphylococcus aureus (MRSA) is the 
leading cause of multidrug resistant (MDR) hospital-
associated infections (HAI) in the U.S   
• MDR infections result in increased morbidity, mortality, cost 
of care, length of hospital stay, and increasingly insusceptible 
to known antimicrobials 
•  Multidrug-resistant (MDR) Acinetobacter baumannii is 
becoming an important healthcare- acquired pathogen in 
hospitals and other health care settings.  
• Acinetobacter baumannii  is an increasing cause of HAI in 
Intensive Care Units (ICUs) in the United States with it 
being the fifth most frequent cause of pneumonia  
• Most antibiotics are natural products or semisynthetic 
derivatives from soil actinomycetes 
 
Methods and findings 
 
MRSA Isolate 48-29: 
zone of inhibition- 23mmMRSA Controls
Sulfa/Trimethoprim : 
zone of inhibition-36mm
Tobramicin- no zone
MRSA Isolate 19-25: 
zone of inhibition
18mm
Fig. 3. Zone of inhibition of U.S. 
MRSA isolates against discs with
KZ extracts
Fig. 4.  
Acinetobacter
Type AN 
controls
Ampicillin: 
zone of 
inhibition-
25mm
Tetracycline:
no zone
Overall summary of MRSA  
susceptibility to extremophile extracts 
a Growth Medium 1 = Modified Bennett’s pH=7.2 
b Growth Medium 2 = Modified Bennett’s pH=7.2, 5% NaCl 
c Growth Medium 3 = Modified Bennett’s pH=9.0, 0.5% Na2CO3  
d NG = No growth of the Actinomycetes producer 
eZone of Inhibition for US HA-MRSA reported is an average of multiple DDAs. 
 
Inhibition of Kazakhstan and US HA-MRSA by Actinomycetes Antagonists 
Antagonist # 
and Source ( pH) 
Zone of Inhibition (Kazakhstan HA-MRSA) mm 
United States HA-MRSA 
Zone of Inhibition
e
 Growth Media 
1
a
 2
b
 3
c
  
2-2      mud (9.1) 0 18 NG 0 
6-12    rhizosphere (8.6) 0 25 NG 0 
18-7    sandy soil (10.0) 13 44 NG 0 
19-25  soil (9.3) 0 35 0 11.5 
33-1    mud (9.6) NG
d
 49 39 10.0 
36-3    meadow soil (8.3) 10 24 23 0 
41-8    saline soil (10.0) 11 29 15 7.0 
48-29  sandy soil (10.0) 0 32 22 20.5 
51-9    rhizosphere (9.5) 10 46 10 0 
58-22  rhizosphere (8.9) 0 18 14 22.5 
72-1    soil (9.6) 0 50 NG 0 
96-1    soil (8.6) 11 26 19 0 
Q4-39 soil (10.0) 0 16 15 0 
Y-45   rhizosphere (9.8) 0 20 16 0 
Methods and findings 
http://www.research.usf.edu/cddi/ 
 
USF Center for Drug Discovery and 
Innovation (CDDI) 
 
• LCMS analysis summary 
• Mass Spectrometry (MS): Agilent 
6120 single quadrupole 
• Ion Mode: electrospray (ESI), positive 
and negative 
• Mass range acquisition: m/z 100-
1200 amu 
• Software: chemstation 
 
• High Performance Liquid 
Chromatography (HPLC): Agilent 
1100 Binary Pump, Well Plate 
autosampler, (2mL vial)  Diode array 
detector (DAD), Thermostatted 
Column Compartment. 
• Column:  Phenomenex kinetex C18 
2.6um, 3.0 x 100 mm 
 
Sample Preparation 
Actinomycetes extracts diluted in Ethanol for 
a concentration of 1mg/mL in a 100 mL insert 
Antimarin 
Quick Dereplication Search: 
(using mass (MS) data observed and source taxonomic information) 
For microbes: 
• Antimarin database (available at the chemodiversity lab)  
 Note (1) the search was based on combined taxonomic and mass 
 information (2) antimarin gathers pure compounds from marine  
 and marine/terrestrial  
 micro-organisms 
• Complementary online data: 
 - Scifinder (exhaustive and  
    fully updated data base) 
 - Dictionary of Natural products 
   (not covered by USF) 
 
 
19-25 
Complex mixture : 
m/z+: 381 
m/z-: 377 
related +/- ions  observed: m/z+: 213, 227 (fragments), 498, 516, 538  
m/z-: 512 (fragment), 550, 560, MW= 515 
Pure compound: m/z+: 512, 530, 552; m/z-: 564, 574, MW= 529 
Mixture: m/z+: 544, 552, 566; m/z-: 588, MW= 543 
Mixture m/z+: 171, 200, 258, 363; m/z-: low abundance, possible MW= 170 
Mixture m/z+: 217, 457, 515; m/z-: 316, 360, 512, 671 
I- possible structures for MW= 515 from sample 19-25 (antimarin) 
m/z(+): [M-H2O+H]
+= 498.3, [M+H]+= 516.2, [M+Na]+= 538.3 Possible fragment or impurity 
Need to be identified (pending) 
m/z (-): [M+Cl]-= 549.9, [M+HCOO]-= 560.2 
Summary and Conclusions 
• Five extracts from Actinomycetes showed distinct  
inhibition zones when tested against US MRSA: 
promising candidates for novel antibiotics 
 
 
• Initial chemical characterization was performed to 
investigate  their antagonistic properties further 
 
• The established approach and methodologies will 
be expanded and applied in future studies 
 
Future directions 
• Screen for producers of antibiotics active against Acinetobacter spp. and other 
gram negative pathogens and other important pathogens (MDRTB) 
 
• Approach from several angles--- 
– bioactive guided fractionation to test which fractions contain active components 
– chemical characterization to identify novel compound   
 
• Use of PCR and traditional culture to identify producer organism - for scale up 
 
• Identification and gene expression studies of dormant genes 
 
• Differential identification of peaks  
– Prepare large batch culture from different growth conditions  
– Compare extracts from conditions where antibody produced and not producing 
– Identify peaks corresponding to active components 
 
 

Acid Fast Stain-MDRTB 
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